Key facts
- This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2022, 15:03.
Eric M. Dube - 04 Jan 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- TVTX
- Reported as of
- 04 Jan 2022
- Net transaction value
- -$521,407
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2022, 15:03:07 UTC
- Prior SEC filing
- 17 Aug 2021
- Next SEC filing
- 26 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 06 Jan 2022.
Change
- Previous filing in this sequence was filed on 17 Aug 2021.
- Current net transaction value: -$521,407.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Sale
- Transaction value
- $147,038
- Shares
- -4,832
- Change %
- -3.1%
- Price
- $30.43
- Shares after
- 152,083
- Date
- 04 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
TVTX
transaction
Common Stock
Sale
- Transaction value
- $309,172
- Shares
- -10,361
- Change %
- -6.8%
- Price
- $29.84
- Shares after
- 141,722
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F2, F3
TVTX
transaction
Common Stock
Sale
- Transaction value
- $65,197
- Shares
- -2,139
- Change %
- -1.5%
- Price
- $30.48
- Shares after
- 139,583
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
Footnote F2
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 to $30.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.38 to $30.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.